INVEST Pitch Perfect winner spotlight: Pleiogenix eyes road ahead for liver disease drug Posted on August 3, 2020 by Nile The company is hoping to close its seed funding round in the next six months and aims to be in a position to seek regulatory approval for its lead asset, PLX888, in acute alcoholic hepatitis in 2023.